Nautilus Biotechnology (NAUT) Share-based Compensation (2020 - 2026)

Nautilus Biotechnology has reported Share-based Compensation for 7 years, with the latest figure at $1.2 million in Q2 2026.

• Quarterly Share-based Compensation fell 32.24% year-over-year to $1.2 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $5.5 million (down 46.13% YoY) and the FY2025 annual result came in at $6.8 million, down 46.11% from the prior year.
• Share-based Compensation declined to $1.2 million in Q2 2026 per NAUT's latest filing, from $1.4 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $7.6 million in Q1 2023 and troughed at $1.2 million in Q2 2026.
• A 5-year average of $2.6 million and a median of $2.6 million in 2022 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2022 and 2023: Share-based Compensation plunged 88.43% in 2022, then jumped 261.28% in 2023.
• Over 5 years, Share-based Compensation stood at $2.8 million in 2022, then climbed by 8.47% to $3.1 million in 2023, then climbed by 1.66% to $3.1 million in 2024, then slumped by 52.91% to $1.5 million in 2025, then dropped by 21.28% to $1.2 million in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $1.2 million, $1.4 million, and $1.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.